Visiongain’s latest report, Women’s Clinical Trials & CROs Market Report 2026-2036, provides detailed forecasts and strategic analysis across trial phase, indication, study design, sponsor type, and service type segments, including technology trends, trade and supply chain dynamics, and competitive positioning.

The global women’s clinical trials and CROs market is valued at US$9.9 billion in 2026 and is projected to reach US$22.3 billion by 2036, at a CAGR of 8.5% during the forecast period. Growth is driven by rising prevalence of women-predominant conditions, expanding regulatory requirements for sex-specific safety evaluation, and increasing adoption of precision medicine and biomarker-driven approaches across reproductive health, oncology, and hormonal disorder indications.

Key Market Insights

• The global women’s clinical trials and CROs market will reach US$22.3 billion by 2036, growing at a CAGR of 8.5%
• Growth is driven by rising disease burden in women-predominant conditions, regulatory mandates for inclusive trial design, and expanding CRO specialisation in women’s health
• Key regions: North America, Europe, Asia Pacific
• Leading companies: IQVIA, ICON Plc, Labcorp, Syneos Health, Charles River Laboratories
• Key trend: Expansion of decentralised and hybrid trial models improving enrolment speed and representativeness across diverse female populations

Download Sample Request

Market Drivers

Rising Prevalence of Women-Predominant Conditions

The steadily rising burden of diseases disproportionately affecting women, including breast and ovarian cancers, endometriosis, polycystic ovary syndrome, lupus, and cardiovascular disorders with sex-specific patterns, has intensified the need for targeted therapeutics and robust clinical evidence. In 2025, the National Cancer Institute projected approximately 316,950 new invasive breast cancer cases in the U.S., underscoring the scale of clinical demand.

Historically, women were underrepresented in pivotal trials, leaving evidence gaps in safety, dosing, and pharmacokinetics. Regulators including the FDA now mandate sex-stratified analyses, making fair representation and women-focused research both a scientific priority and a commercial growth driver for CROs with specialist capability in this area.

Regulatory Momentum and Global Policy Initiatives

Regulatory and policy initiatives are actively reshaping trial design and CRO operations by requiring sponsors to correct longstanding exclusion of women from clinical research. In 2025, the WHO announced a global Task Force dedicated to ensuring ethical, safe, and scientifically sound inclusion of pregnant and breastfeeding women in clinical research, addressing populations that have historically been excluded by default.

The U.S. FDA has advanced more explicit guidance including the draft E21 guideline on inclusion of pregnant and breastfeeding participants, covering risk assessment, study justification, and operational safeguards. NIH policies require federally funded studies to include women and report outcomes by sex, turning inclusion into a condition for research eligibility. These frameworks are compelling sponsors to redesign study protocols, expand eligibility criteria, create pregnancy safety monitoring plans, build long-term registries, and adopt decentralised platforms to improve access for diverse female populations.

Technology & Innovation

Precision Medicine and Biomarker-Driven Women’s Health Programmes

The rise of precision medicine in women’s health is rapidly expanding the number of biomarker-driven clinical programmes requiring highly specialised trial infrastructure. As oncology, immunology, reproductive health, and endocrine research move toward molecularly defined subgroups, trials increasingly rely on genomic assays, hormonal biomarkers, pharmacogenomics, and molecular signatures that differ markedly across female life stages.

CROs are expanding integrated biomarker services, genomic data platforms, advanced bioanalytical laboratories, and adaptive trial operational systems to meet these demands. As precision medicine extends into fertility, endometriosis, maternal-foetal medicine, breast oncology, and hormonal disorders, smaller and more stratified cohorts require faster site activation, laboratory harmonisation across geographies, and sophisticated statistical designs, driving steady growth in outsourcing to CROs with specialised biomarker capabilities.

Trade & Supply Chain Dynamics

U.S. trade tariffs are increasing operational costs across the global women’s clinical trials and CRO market by raising prices for imported laboratory reagents, specialised medical devices, comparator drugs, and biomanufacturing inputs. Women’s health trials are particularly exposed because pregnancy-safe diagnostics, hormone-assay kits, and specialised imaging tools have narrow supply bases, making them especially sensitive to import-related cost increases.

U.S.-China tariff friction is also disrupting the movement of biospecimens, central laboratory operations, and data-processing hardware, forcing rerouting or duplication of services and creating delays in reproductive health and oncology programmes. Sponsors are responding by shifting site activation toward CRO networks in India, Southeast Asia, and Europe, and diversifying supplier and central laboratory arrangements to build resilience into trial operations.

Commercial Impact

• Cost pressure: Rising input costs for specialised diagnostics, reagents, and trial equipment are increasing baseline trial budgets and limiting the number of concurrent programmes sponsors can run
• Supply chain shifts: Companies are diversifying suppliers, restructuring diagnostic consumable manufacturing, and distributing central laboratory functions across multiple countries to reduce tariff exposure
• Operational complexity: Women’s trials already require heightened safety oversight and specialised endpoints, meaning even modest increases in cost or logistical friction can extend development timelines
• Competitive positioning: Elite CROs with supply chain expertise, global site coordination, and tariff-compliant procurement are gaining new outsourcing mandates as sponsors seek to manage cost volatility

Market Opportunities

Decentralised Trials and Digital Tools Improving Enrolment and Representativeness

Decentralised and hybrid trial models are transforming how women’s health studies are designed and executed. Electronic health record-driven recruitment, remote monitoring platforms, and digital engagement tools are improving enrolment speed, broadening access to diverse female populations, and reducing geographic barriers to participation.

In 2025, Lindus Health launched hybrid women’s health trials in oncology and reproductive medicine, leveraging more than 30 million electronic health records to double enrolment speed compared to traditional CRO approaches, with a focus on diverse female cohorts including underrepresented groups in oncology. Lambda Therapeutic Research expanded its portfolio to more than 15 women’s health trials covering contraception, assisted reproductive technology, hormone replacement therapy, and postmenopausal osteoporosis across more than 700 global sites, positioning as a full-service CRO for women’s health research.

Expansion of Sex-Specific Safety Requirements Across the Drug Lifecycle

Expanding requirements for sex-specific safety evaluation across the full drug lifecycle are generating sustained demand for specialist CRO support. Regulators expect drugs to demonstrate safety profiles that reflect real-world female use patterns, including variations tied to reproductive age, hormonal status, and comorbidities that differ by sex. Post-marketing surveillance requirements including FDA’s Drug Trials Snapshots programme demand transparent reporting on sex-linked safety, requiring ongoing Phase IV studies, pregnancy-exposure registries, and long-term safety follow-up built around women’s use profiles.

CROs carry much of this operational load, including risk management plans, signal detection, pharmacovigilance analytics, and registry management. For reproductive health, oncology, and cardiometabolic indications, the lifecycle burden is especially high, turning safety analysis into a continuous process that steadily increases demand for specialised CRO expertise in monitoring, data science, and long-term evidence generation.

Competitive Landscape

The major players operating in the women’s clinical trials and CROs market include Amgen, AstraZeneca, Bayer, Charles River Laboratories, F. Hoffmann-La Roche, GSK plc, ICON Plc, IQVIA, Johnson & Johnson, Labcorp, Lilly USA, Medpace, Medtronic, Merck & Co, Novartis AG, Pfizer, Syneos Health, Thermo Fisher Scientific, and WuXi AppTec.

These companies are strengthening their market positions through M&A, R&D investment, strategic collaborations, and expansion of specialised women’s health trial capabilities, with increasing focus on decentralised models, biomarker integration, and regulatory compliance services.

Recent Developments

• 2025 – Lindus Health launched hybrid women’s health trials in oncology and reproductive medicine, leveraging more than 30 million electronic health records and digital recruitment to double enrolment speed compared to traditional CROs, with a focus on diverse and underrepresented female cohorts
• 2025 – Lambda Therapeutic Research expanded its portfolio to more than 15 women’s health trials covering contraception, assisted reproductive technology, hormone replacement therapy, and postmenopausal osteoporosis, operating across more than 700 global sites as a full-service CRO for women’s health

Frequently Asked Questions

What is driving growth in the women’s clinical trials and CROs market?

Growth is driven by rising prevalence of women-predominant conditions, expanding regulatory mandates for sex-specific safety evaluation and inclusive trial design, and increasing adoption of precision medicine and biomarker-driven approaches across reproductive health, oncology, and hormonal disorder indications.

How are trade and supply chain dynamics affecting the market?

U.S. tariffs on laboratory reagents, specialised diagnostics, and biomanufacturing inputs are increasing trial costs and disrupting cross-border supply chains. This is accelerating supplier diversification, central laboratory restructuring, and a shift in site activation toward CRO networks in India, Southeast Asia, and Europe.

Who are the leading companies in the market?

Key players include IQVIA, ICON Plc, Labcorp, Syneos Health, Charles River Laboratories, Thermo Fisher Scientific, and WuXi AppTec.

Download Sample Request

Related Reports

Pharma Contract Sales Market Report 2026–2036

Gene Therapy R&D Market Report 2026–2036

Clinical Trial Supply and Logistics Market for Pharma 2026–2036

About Visiongain

Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.

Media Contact

press@visiongain.com
+44 (0)20 7336 6100
www.visiongain.com